Quest Diagnostics (DGX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues reached $2.49 billion, up 8.5% year-over-year, with 4.2% organic growth driven by new customer wins, expanded business, and recent acquisitions including LifeLabs, Allina Health, and three NY physician group labs.

• Reported diluted EPS for Q3 was $1.99, up 1.5% year-over-year; adjusted diluted EPS was $2.30, up 3.6% year-over-year.

• Net income attributable to Quest Diagnostics was $226 million, up 0.5% from Q3 2023; adjusted net income was $262 million.

• Consumer-initiated testing platform grew revenues over 40% year-over-year, with repeat customer rate rising to 30%.

• Strategy centers on advanced diagnostics, operational improvements via automation and AI, and accretive acquisitions.

Financial highlights

• Q3 consolidated revenues were $2.49 billion, up 8.5% year-over-year; organic revenues up 4.2%.

• Diagnostic Information Services revenues rose 9% year-over-year; DS revenues declined 7.9% due to lower risk assessment and IT business revenues.

• Total volume increased 5.5%, with acquisitions contributing 5% to total volume.

• Reported operating income was $330 million (13.3% margin); adjusted operating income was $385 million (15.5% margin).

• Cash from operations year-to-date was $870 million, up from $745 million last year.

Outlook and guidance

• 2024 revenue guidance raised to $9.8–$9.85 billion, driven by acquisitions.

• Reported EPS guidance: $7.55–$7.70; adjusted EPS: $8.85–$8.95.

• Cash from operations expected at $1.3 billion; capital expenditures at $420 million.

• Hurricane Milton expected to negatively impact Q4 revenue by $15 million and EPS by $0.08.

• Eight acquisitions are expected to close in 2024, supporting accelerated growth in 2025.